Rezolute Inc (RZLT)

$3.15 -0.09 (-2.78%)
Market Cap 309.71M
Revenue (ttm) 0.00
Net Income (ttm) -74.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,100,257
Avg Vol 8,124,488
Day's Range N/A - N/A
Shares Out 92.73M
Stochastic %K 49%
Beta 0.39
Analysts Strong Sell
Price Target $4.25

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 206 4507
Address:
275 Shoreline Drive, Suite 500, Redwood City, United States
oaksapollo
oaksapollo Feb. 3 at 8:31 PM
$RZLT need FDA news, they must be waiting for official minutes, shouldn’t be taking this long under breakthrough designation
0 · Reply
niock
niock Feb. 3 at 4:14 PM
$RZLT
0 · Reply
MrBlockchain
MrBlockchain Feb. 3 at 3:03 PM
$RZLT Huh. Added.
0 · Reply
Monty3030
Monty3030 Feb. 3 at 2:54 PM
$RZLT Looking for an update next week or the week after on CHI, when earnings are announced. Let's see if the FDA gives them the green light!
0 · Reply
Monty3030
Monty3030 Feb. 2 at 3:19 PM
$RZLT 29.21% short interest 8.29 days to cover
0 · Reply
Axeknight
Axeknight Feb. 2 at 2:44 PM
$RZLT
0 · Reply
oaksapollo
oaksapollo Jan. 30 at 7:49 PM
$RZLT Vanguard, 5M shares, appears to be a brand new position. https://ir.stockpr.com/rezolutebio/sec-filings-email/content/0000102909-26-000261/primary_doc.html
1 · Reply
JuliusW
JuliusW Jan. 30 at 4:33 PM
$RZLT $CADL Holding.
0 · Reply
Chefbyday
Chefbyday Jan. 30 at 12:58 AM
$RZLT wee hoo !! 🙌🏻
0 · Reply
mocool
mocool Jan. 29 at 11:35 PM
$RZLT just down with the market or is something up?
0 · Reply
Latest News on RZLT
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Jan 31, 2026, 8:04 AM EST - 3 days ago

SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Alger Small Cap Growth Fund Q4 2025 Portfolio Update

Jan 26, 2026, 3:54 AM EST - 8 days ago

Alger Small Cap Growth Fund Q4 2025 Portfolio Update

EXAS GH NBIS NTRA WIX

INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Jan 25, 2026, 8:21 PM EST - 8 days ago

INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Jan 23, 2026, 10:33 AM EST - 11 days ago

RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Jan 16, 2026, 10:27 AM EST - 18 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

Jan 14, 2026, 11:58 AM EST - 20 days ago

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Jan 8, 2026, 1:12 PM EST - 26 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Jan 7, 2026, 7:00 AM EST - 27 days ago

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Jan 3, 2026, 7:41 AM EST - 4 weeks ago

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Dec 31, 2025, 12:10 PM EST - 4 weeks ago

INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Dec 19, 2025, 10:08 AM EST - 6 weeks ago

REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

RZLT: Rezolute, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Dec 17, 2025, 4:31 PM EST - 6 weeks ago

RZLT: Rezolute, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Dec 12, 2025, 3:00 PM EST - 7 weeks ago

RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure

Dec 11, 2025, 7:59 PM EST - 7 weeks ago

Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Dec 11, 2025, 2:39 PM EST - 7 weeks ago

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript

Dec 11, 2025, 2:22 PM EST - 7 weeks ago

Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript

BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Dec 11, 2025, 10:39 AM EST - 7 weeks ago

BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Rezolute's rare disease drug fails main goal in late-stage trial

Dec 11, 2025, 7:05 AM EST - 7 weeks ago

Rezolute's rare disease drug fails main goal in late-stage trial

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Dec 11, 2025, 7:00 AM EST - 7 weeks ago

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute: sunRIZE And upLIFT Trials Could Drive The Next Move

Dec 8, 2025, 9:23 PM EST - 2 months ago

Rezolute: sunRIZE And upLIFT Trials Could Drive The Next Move

Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript

Nov 10, 2025, 7:51 PM EST - 3 months ago

Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 5:30 PM EST - 3 months ago

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 3 months ago

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Nov 5, 2025, 7:30 AM EST - 3 months ago

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Rezolute to Participate in Upcoming Investor Conferences

Oct 15, 2025, 8:00 AM EDT - 3 months ago

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 17, 2025, 4:05 PM EDT - 4 months ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug

Sep 16, 2025, 4:36 PM EDT - 5 months ago

Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug

Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 12, 2025, 9:38 AM EDT - 5 months ago

Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Sep 2, 2025, 7:30 AM EDT - 5 months ago

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Aug 20, 2025, 7:30 AM EDT - 5 months ago

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Jul 22, 2025, 7:30 AM EDT - 7 months ago

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Jul 9, 2025, 7:30 AM EDT - 7 months ago

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025, 8:00 AM EDT - 8 months ago

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 9 months ago

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025, 8:00 AM EDT - 9 months ago

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

May 1, 2025, 3:57 AM EDT - 9 months ago

Rezolute: RZ402 Could Be A Surprise Candidate In The Making

Rezolute, Inc. Announces Closing of Underwritten Offering

Apr 25, 2025, 4:30 PM EDT - 10 months ago

Rezolute, Inc. Announces Closing of Underwritten Offering

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Apr 23, 2025, 3:50 PM EDT - 10 months ago

Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Apr 23, 2025, 8:05 AM EDT - 10 months ago

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Apr 23, 2025, 8:00 AM EDT - 10 months ago

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Mar 26, 2025, 7:30 AM EDT - 11 months ago

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

oaksapollo
oaksapollo Feb. 3 at 8:31 PM
$RZLT need FDA news, they must be waiting for official minutes, shouldn’t be taking this long under breakthrough designation
0 · Reply
niock
niock Feb. 3 at 4:14 PM
$RZLT
0 · Reply
MrBlockchain
MrBlockchain Feb. 3 at 3:03 PM
$RZLT Huh. Added.
0 · Reply
Monty3030
Monty3030 Feb. 3 at 2:54 PM
$RZLT Looking for an update next week or the week after on CHI, when earnings are announced. Let's see if the FDA gives them the green light!
0 · Reply
Monty3030
Monty3030 Feb. 2 at 3:19 PM
$RZLT 29.21% short interest 8.29 days to cover
0 · Reply
Axeknight
Axeknight Feb. 2 at 2:44 PM
$RZLT
0 · Reply
oaksapollo
oaksapollo Jan. 30 at 7:49 PM
$RZLT Vanguard, 5M shares, appears to be a brand new position. https://ir.stockpr.com/rezolutebio/sec-filings-email/content/0000102909-26-000261/primary_doc.html
1 · Reply
JuliusW
JuliusW Jan. 30 at 4:33 PM
$RZLT $CADL Holding.
0 · Reply
Chefbyday
Chefbyday Jan. 30 at 12:58 AM
$RZLT wee hoo !! 🙌🏻
0 · Reply
mocool
mocool Jan. 29 at 11:35 PM
$RZLT just down with the market or is something up?
0 · Reply
niock
niock Jan. 29 at 2:42 PM
$RZLT
0 · Reply
Axeknight
Axeknight Jan. 28 at 3:46 PM
$RZLT
0 · Reply
oaksapollo
oaksapollo Jan. 27 at 9:57 PM
$RZLT There is no question by now they have met with FDA. The only question is when do they choose to tell us the outcome? Do they wait for official meeting minutes (could be up to 30 days) or was the messaging so clear they can update without minutes? So could be news tomorrow, could be mid-late Feb. Either way, not far off.
0 · Reply
Smiles_P
Smiles_P Jan. 27 at 9:42 PM
$RZLT I’ve never been so sure that news was imminent…one of these days this will open over $5…
0 · Reply
tommycman
tommycman Jan. 27 at 4:27 PM
$RZLT "on the road again, I just can't wait to get on that road again"... Yeh Haw!
1 · Reply
marti837
marti837 Jan. 27 at 4:23 PM
$RZLT more short
0 · Reply
Monty3030
Monty3030 Jan. 27 at 3:58 PM
$RZLT I'm seeing large call options being bought between $15 and 22.50 strike price for January 2027 expiration.
0 · Reply
MrBlockchain
MrBlockchain Jan. 27 at 12:30 PM
$RZLT Hmmm. It's almost time.
0 · Reply
Namche
Namche Jan. 26 at 4:35 PM
$RZLT
0 · Reply
Monty3030
Monty3030 Jan. 26 at 4:28 PM
$RZLT Every squeeze starts with someone calling it easy money!
0 · Reply
marti837
marti837 Jan. 26 at 4:17 PM
$RZLT short. easy money
0 · Reply
Monty3030
Monty3030 Jan. 26 at 3:14 PM
$RZLT FYI, It looks like all 13k of those call contracts at $5 strike for February did not go through. I only see a total of 5k call contracts at the$5 strike. Let's see what happens.
0 · Reply